Skip to main content

Advertisement

SpringerLink
Log in

The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer

  • Review Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Peritoneal metastasis, either synchronous or metachronous, is commonly seen in gastric cancer. It is associated with a poor prognosis, with a median survival of less than one year. The outcomes are not significantly improved by the use of systemic chemotherapy. We review the relevant literature on the role of HIPEC in gastric cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used in three situations in gastric cancer. Besides its role as a definitive treatment in patients with established peritoneal metastasis (PM), it has been used as a prophylaxis against peritoneal recurrence after curative surgery and also as a palliative treatment in advanced peritoneal metastasis with intractable ascites. While prophylactic HIPEC has been shown to reduce peritoneal recurrence and improve survival in many randomised trials, palliative HIPEC can reduce the need for frequent paracentesis. Although CRS with HIPEC has shown promise in increasing the survival of selected patients with established PM from gastric cancer, larger studies are needed before this can be accepted as a standard of care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; Available from: http://globocan.iarc.fr, accessed on 01.03.2015

  2. Abbasi SY, Taani HE, Saad A, Badheeb A, Addasi A (2011) Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes. Gastrointest Cancer Res 4:122–127

    PubMed  PubMed Central  Google Scholar 

  3. Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH (2014) Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int J Cancer 134:622–628

    Article  CAS  PubMed  Google Scholar 

  4. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K, Group JCO (2008) D2 lymphadenectomy alone or with Para-aortic Nodal Dissection for Gastric Cancer. N Engl J Med 359:453–462

    Article  CAS  PubMed  Google Scholar 

  5. Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, Schmidt C, Weber SM, Votanopoulos K, Maithel SK, Pawlik TM (2014) Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg 219:664–675

    Article  PubMed  Google Scholar 

  6. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, (2003) De Stefano A on behalf of the Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg; 90: 1113–1119

  7. Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, Lin HJ, Li AF, Lui WY (2003) Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 27:153–158

    PubMed  Google Scholar 

  8. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y (2007) Kurita A, and Arai K for the ACTS-GC Group Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. N Engl J Med 357:1810–1820

    Article  CAS  PubMed  Google Scholar 

  9. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, SH N (2012) CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 28:379–315–321

    Google Scholar 

  10. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ (2006) MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

    Article  CAS  PubMed  Google Scholar 

  11. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS (2012) Updated analysis of SWOG-directed intergroup Study 0116:A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327–2333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Liang JW, Zheng ZC, Yu T, Wang X, Zhang JJ (2014) Is postoperative adjuvant chemoradiotherapy efficacious and safe for gastric cancer patients with D2 lymphadenectomy? A meta-analysis of the literature. Eur J Surg Oncol 40:1614–1621

    Article  CAS  PubMed  Google Scholar 

  13. Xiong B, Ma L, Cheng Y, Zhang C (2014) Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: an updated meta-analysis of randomized controlled trials. Eur J Surg Oncol 40:1321–1330

    Article  CAS  PubMed  Google Scholar 

  14. Cao J, Qi F, Liu T (2014) Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis. Scand J Gastroenterol 49:690–704

    Article  CAS  PubMed  Google Scholar 

  15. Yonemura Y, Fujimura T, Nishimura G, FallaR ST, Katayama K, Tsugawa K, Fushida S, Miyazaki I, Tanaka M, Endou Y, Sasaki T (1996) Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 119:437–444

    Article  CAS  PubMed  Google Scholar 

  16. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies results of the EVOCAPE 1 multicentric prospective Study. Cancer 88:358–363

    Article  CAS  PubMed  Google Scholar 

  17. Kim JG, Ryoo B-Y, Park YH, Kim BS, Kim TY, Im YH, Kang YK (2008) Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 61:301–307

    Article  CAS  PubMed  Google Scholar 

  18. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403

    Article  PubMed  Google Scholar 

  19. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Article  PubMed  Google Scholar 

  20. Bilici A (2014) Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol 20:3905–3915

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Article  CAS  PubMed  Google Scholar 

  22. Hong SH, Shin YR, Roh SY, Jeon EK, Song KY, Park CH, Jeon HM, Hong YS (2013) Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer 16:290–300

    Article  CAS  PubMed  Google Scholar 

  23. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, Fukuda H, Ohtsu A (2013) Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. randomized phase III Study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106) for the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol 43:972–980

    Article  PubMed  Google Scholar 

  24. Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Li Y (2010) Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol 36:1131–1138

    Article  CAS  PubMed  Google Scholar 

  25. Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier. Cancer Treat Res 82:53–63

    Article  CAS  PubMed  Google Scholar 

  26. Sugarbaker PH, Yu W, Yonemura Y (2003) Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 21:233–248

    Article  PubMed  Google Scholar 

  27. Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69–76

    Article  PubMed  Google Scholar 

  28. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multiinstitutional study of 1,290 patients. Cancer 116:5608–5618

    Article  PubMed  Google Scholar 

  29. Iitsuka Y, Kaneshima S, Tanida 0, Takeuchi T, Koga S. (1979) Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer; 44:1476–1480.

  30. González-Moreno S, González-Bayón LA, Ortega-Pérez G (2010) Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2:68–75

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sticca RP, Dach BW (2003) Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 12:689–701

    Article  PubMed  Google Scholar 

  32. Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, Schlag P (1989) Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 16(Suppl 6):83–97

    CAS  PubMed  Google Scholar 

  33. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, Tsuburaya A (2012) Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy. Ann Surg Oncol 19:1568–1574

    Article  PubMed  Google Scholar 

  34. Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, Ichinose M, Miura M, Li Y (2010) Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2:85–97

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T (1999) Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 72:60–64

    Article  CAS  PubMed  Google Scholar 

  36. Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D (2005) The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 12:347–353

    Article  PubMed  Google Scholar 

  37. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T (1988) Prophylactic cancer therapy for peritoneal recurrence of gastric by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232–237

    Article  CAS  PubMed  Google Scholar 

  38. Fujimura T, Yonemura Y, Muraoka K, et al. (1994) Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 18:150–155

    Article  CAS  PubMed  Google Scholar 

  39. Hamazoe R, Maeta M, Kaibara N (1994) Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer - final results of a randomised controlled study. Cancer 73:2048–2052

    Article  CAS  PubMed  Google Scholar 

  40. Ikeguchi M, Kondou A, Oka A, Takamura H, Hirono Y, Sahara H, Ninomiya I, Matsumoto H, Tsugawa K, Nishimura G (1995) Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 161:581–586

    CAS  PubMed  Google Scholar 

  41. Hirose K, Katayama K, Iida A, Yamaguchi A, Nakagawara G, Umeda S, Kusaka Y (1999) Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology 57:106–114

    Article  CAS  PubMed  Google Scholar 

  42. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T (1999) Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 85:529–534

    Article  CAS  PubMed  Google Scholar 

  43. Kim JY, Bae HS (2001) A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer 4:27–33

    Article  CAS  PubMed  Google Scholar 

  44. Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, Sasaki T (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. Hepatogastroenterol 48:1776–1782

    CAS  Google Scholar 

  45. Yonemura Y, Shinbo M, Hagiwara A, Shimada S, Nakajima T, Ikeda S, Pkamura H, Hirano M, Mizuno M, Endou Y, Miura M, Mizumoto Y (2008) Treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells. Gastroenterological Surgery 31:802–812

    Google Scholar 

  46. Mi DH, Li Z, Yang K-H, Cao-N LA, Tian J-H, Santesso N, Ma B, Chen Y-L, Liu Y-L (2013) Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: A systematic review and meta-analysis of randomised controlled trials. Int J Hyperth 29:156–167

    Article  CAS  Google Scholar 

  47. Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, Liang J, Xu H (2012) Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer 12:526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Huang JY, Xu YY, Sun Z, Zhu Z, Song YX, Guo PT, You Y, Xu HM (2012) Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: A Meta-analysis. Asia Pacific J Cancer Prev 13:4379–4385

    Article  Google Scholar 

  49. Yan TD, Black D, Suqarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intra-peritoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14:2702–2713

    Article  PubMed  Google Scholar 

  50. Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L (2014) Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 40:12–26

    Article  CAS  PubMed  Google Scholar 

  51. Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR (2004) Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 10:2727–2730

    Article  PubMed  PubMed Central  Google Scholar 

  52. Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, Piaton E, Garofalo A (2014) GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicentre phase III study. BMC Cancer 14:183

    Article  PubMed  PubMed Central  Google Scholar 

  53. Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Arimizu N (1988) Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 208:36–41

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Fujimoto S, Shrestha RD (1990) Kokubun, M, Kobayashi K, Kiuchi S, Konno C, Ohta M, Takahashi M, Kitsukawa Y, Mizutani M: Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 212:592–596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, Kosaka T, Yamaguchi A, Miwa K, Miyazaki I (1991) Hyperthermochemotherapy combined with cytoreductive surgery for treatment of gastric cancer with peritoneal dissemination. World J Surg 15:530–535

    Article  CAS  PubMed  Google Scholar 

  56. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, Sumida M, Ohkubo H (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884–891

    Article  CAS  PubMed  Google Scholar 

  57. Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, François Y, Vignal J, Gilly FN (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 139:20–26

    Article  CAS  PubMed  Google Scholar 

  58. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N (2005) Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 92:370–375

    Article  CAS  PubMed  Google Scholar 

  59. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D (2010) Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: A multi-institutional Study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol; 17:2370–2377

  60. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18:1575–1581

    Article  PubMed  PubMed Central  Google Scholar 

  61. Verwaal V, van Ruth S, De Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patientswith peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3747

    Article  PubMed  Google Scholar 

  62. Gill RS, Al-adra D, Nagendran J, Campbell S, Shi X, HaaseE SD (2011) Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidity. J Surg Oncol 104:692–698

    Article  PubMed  Google Scholar 

  63. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M (2008) Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 98:273–276

    Article  CAS  PubMed  Google Scholar 

  64. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T (2003) Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 12:635–648

    Article  PubMed  Google Scholar 

  65. Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, Miura M, Ikeda M, Ikeda S, Nakajima G, Yonemura J, Yuuba T, Masuda S, Kimura H, Matsuki N (2009) Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 100:311–316

    Article  CAS  PubMed  Google Scholar 

  66. Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, Takao N, Yonemura Y (2014) Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol 21:1147–1152

    Article  PubMed  Google Scholar 

  67. Glehen O, Kwiatkowski F, Sugarbaker PH (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the Management Of Peritoneal Carcinomatosis From Colorectal Cancer: A multi-institutional Study. J Clin Oncol 22:3284–3292

    Article  CAS  PubMed  Google Scholar 

  68. Scaringi S, Kianmanesh R, Sabate JM, Facchiano E, Jouet P, Coffin B, Parmentier G, Hay JM, Flamant Y, Msika S (2008) Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: A single western center experience. Eur J Surg Oncol 34:1246–1252

    Article  CAS  PubMed  Google Scholar 

  69. Königsrainer I, Horvath P, Struller F, Königsrainer A, Beckert S (2014) Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer 14:117–122

    Article  PubMed  PubMed Central  Google Scholar 

  70. Yang QM, Bando E, Kawamura T, Tsukiyama G, Nemoto M, Yonemura Y, Furukawa H (2006) The diagnostic value of PETCT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho 33:1817–1821

    CAS  PubMed  Google Scholar 

  71. Koh JL, Yan TD, Glenn D, Morris DL (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16:327–333

    Article  PubMed  Google Scholar 

  72. Valle M, Garofalo A (2006) Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol 32:625–627

    Article  PubMed  Google Scholar 

  73. Sommariva A, Zagonel V, Rossi CR (2012) The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 19:3737–3744

    Article  PubMed  Google Scholar 

  74. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC (1989) Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63:364–367

    Article  CAS  PubMed  Google Scholar 

  75. Husain A, Bezjak A, Easson A (2010) Malignant ascites symptom cluster in patients referred for paracentesis. Ann Surg Oncol 17:461–469

    Article  PubMed  Google Scholar 

  76. Garofalo A, Valle M, Garcia J, Sugarbaker PH (2006) Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 32:682–685

    Article  CAS  PubMed  Google Scholar 

  77. Facchiano E, Scaringi S, Kianmanesh R, Sabate JM, Castel B, Flamant Y, Coffin B, Msika S (2008) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 34:154–158

    Article  CAS  PubMed  Google Scholar 

  78. Facchiano E, Risio D, Kianmanesh R, Msika S (2012) Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. Ann Surg Oncol 19:2946–2950

    Article  PubMed  Google Scholar 

  79. Valle M, Van der Speeten K, Garofalo A (2009) Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100:331–334

    Article  CAS  PubMed  Google Scholar 

  80. Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI (2014) Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 21:1474–1479

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Cancer Institute (WIA), Chennai, 600036, India

    Ramakrishnan Ayloor Seshadri

  2. Department of Surgical oncology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, 69495, Pierre-Bénite Cedex, France

    Olivier Glehen

  3. Université Lyon 1, EMR 3738, 69600, Oullins, France

    Olivier Glehen

Authors
  1. Ramakrishnan Ayloor Seshadri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Glehen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivier Glehen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seshadri, R.A., Glehen, O. The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer. Indian J Surg Oncol 7, 198–207 (2016). https://doi.org/10.1007/s13193-016-0502-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-016-0502-8

Keywords

Search

Navigation